CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Miltenyi Biomedicine GmbH
Incyte Corporation
Amgen
Dren Bio
BeOne Medicines
Miltenyi Biomedicine GmbH
AstraZeneca
BeOne Medicines
BeOne Medicines
Quetzal Therapeutics
AVM Biotechnology Inc
BeOne Medicines
AstraZeneca
Immunome, Inc.
BeOne Medicines
BeOne Medicines
Orca Biosystems, Inc.
BeOne Medicines
BeOne Medicines
Janssen Research & Development, LLC
Nurix Therapeutics, Inc.
Kura Oncology, Inc.
Pfizer
Incyte Corporation
Nurix Therapeutics, Inc.
Eilean Therapeutics
Janssen Research & Development, LLC
Novartis
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Genmab
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Merck Sharp & Dohme LLC
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Grifols Therapeutics LLC
Chordia Therapeutics, Inc.
Janssen Research & Development, LLC
AbbVie
Merck Sharp & Dohme LLC
GluBio Therapeutics Inc.
Janssen Cilag S.A.S.
AstraZeneca
Janssen Research & Development, LLC